Dr. Breder joined Supernus Pharmaceuticals in September 2006 as the Vice President of the Clinical Development group. Prior to joining Supernus, he served as Group Director, Neuroscience Global Clinical Research at Bristol-Myers Squibb in Wallingford, CT, where he worked for several years in a variety of Phase III/IV programs. These projects spanned across several areas including psychosis, depression, pharmacotherapy of alcoholism and metabolics. At Bristol-Myers Squibb, Dr. Breder also served as the Co-chairperson for a Neuroscience Exploratory Development Team. Before BMS, Chris was at Purdue Pharma LP, Division of Medical Research, where he worked as Clinical Leader for several projects that included the development of new formulations. At Purdue, he was also clinical representative to the licensing group and Strategic Therapeutic team. Dr. Breder also served as Assistant Professor in the Department of Anesthesiology, Division of Neuroanesthesiology, at the Columbia University, Presbyterian Hospital.

Dr. Breder completed his residency in anesthesiology, clinical fellowship in Neuroanesthesiology and post-doctoral fellowship in molecular neurobiology at the Johns Hopkins University. He obtained his Doctor of Medicine degree at The University of Chicago, Pritzker School of Medicine; his Doctor of Philosophy degree at The University of Chicago, Committee on Neurobiology; and his BS in Chemistry at The American University (Summa cum Laude).